Company profile
CARDIFF ONCOLOGY, INC.
NASDAQ:CRDFBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ONVANSERTIB | phase2 | — | 6 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03414034 | phase2 | completed | 2018-08-14 | 2023-10-16 | Cardiff Oncology | Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer |
| NCT03303339 | phase1_2 | completed | 2017-11-17 | 2021-11-17 | Cardiff Oncology | Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML) |
| NCT03829410 | phase1_2 | completed | 2019-06-24 | 2024-01-29 | Cardiff Oncology | Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation |
| NCT04752696 | phase2 | completed | 2021-05-25 | 2024-12-24 | Cardiff Oncology | Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma |
| NCT05593328 | phase2 | completed | 2023-03-17 | 2024-12-09 | Cardiff Oncology | Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation |
FDA applications (0)
No records yet.